CoChat

The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis

Open access
Li, Yang, Hu, Liyi, Xia, Qinghong, Yuan, Yongqiang, Mi, Yonghua · 2017 · International Urology and Nephrology

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

PURPOSE: The effects of metformin on the prognosis of kidney cancer patients with diabetes are in controversial. The present study is conducted to classify the association of metformin use with the survival of patients with kidney cancer. METHODS: Electronic databases, namely PubMed and Web of Science, were used to search the eligible studies up to December, 2016. Pooled hazard ratio (HR) and its corresponding 95% confidence interval (95% CI) were calculated. It was considered as statistically significant when P value was <0.05. RESULTS: Eight cohorts were eligible for the present meta-analysis, including 254,329 kidney cancer patients. The combined HR suggested that the use of metformin could improve the overall survival (OS) (HR 0.643, 95% CI 0.520-0.795, P < 0.001) and cancer-specific survival (CSS) (HR 0.618, 95% CI 0.446-0.858, P = 0.004) in kidney cancer patients. In subgroup analysis, positive associations were found between metformin use and OS/CSS of localized renal cell carcinoma patients (OS: HR 0.634, 95% CI 0.440-0.913, P = 0.014; CSS: HR 0.476, 95% CI 0.295-0.768, P = 0.002). Moreover, we also found that the use of metformin could reduce the risk of death in kidney cancer patients (HR 0.711, 95% CI 0.562-0.899, P = 0.004). CONCLUSION: Our findings suggest that the use of metformin is in favor of the prognosis of patients with kidney cancers. Further investigations are needed to evaluate the prognostic value of metformin on kidney cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11255-017-1548-4

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The procedure of the search strategy
Fig. 1 The procedure of the search strategyCC BY · PubMed Central
Fig. 2 Association between metformin exposure and OS of kidney cancer patients. a All studies with excluding the source of heterogeneity; subgroup analysis, b studies related with localized RCC, c studies associated with North American patients
Fig. 2 Association between metformin exposure and OS of kidney cancer patients. a All studies with excluding the source of heterogeneity; subgroup analysis, b studies related with localized RCC, c studies associated with North American patientsCC BY · PubMed Central
Fig. 3 Relationship of metformin exposure with CSS of kidney cancer patients. a All studies with omission of the studies contributed to the heterogeneity; subgroup analysis, b studies in relation to localized RCC
Fig. 3 Relationship of metformin exposure with CSS of kidney cancer patients. a All studies with omission of the studies contributed to the heterogeneity; subgroup analysis, b studies in relation to localized RCCCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 41

Metadata

Authors
Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y.
Affiliations
Chongqing Medical University (CN)
Venue
International Urology and Nephrology
Published
2017-03-07
Volume
49
Issue
6
Pages
975-981
ISSN
  • 0301-1623 (ISSN-L)
  • 1573-2584
OpenAlex
W2593712675
Cited by
38
References
20
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 3
FWCI
0.44
Type
journal article
Language
en
Open access
Locations
  • International Urology and Nephrology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
metformin, kidney cancer, renal cell carcinoma, diabetes mellitus, overall survival, cancer-specific survival, prognosis, drug repurposing
MeSH terms
Carcinoma, Renal Cell, Diabetes Mellitus, Humans, Hypoglycemic Agents, Kidney Neoplasms, Metformin, Survival Rate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.